Aghazadeh MA, Frankel J, Belanger M, et al.. National Comprehensive Cancer Network favorable intermediate-risk prostate cancer – is active surveillance appropriate? J Urol 2018;199:1196–1201.

• Crossref
• PubMed
Aghazadeh MA, Frankel J, Belanger M, . National Comprehensive Cancer Network favorable intermediate-risk prostate cancer – is active surveillance appropriate? J Urol 2018;199:1196–1201.10.1016/j.juro.2017.12.04929288120)| false
• Search Google Scholar
• Export Citation

Messing EM, Manola J, Yao J, et al.. Immediate versus deferred androgen deprivation treatment in patients with node-positive cancer after radical prostatectomy and pelvic lymphadenopathy. Lancet Oncol 2006;7:472–479.

• Crossref
• PubMed
Messing EM, Manola J, Yao J, . Immediate versus deferred androgen deprivation treatment in patients with node-positive cancer after radical prostatectomy and pelvic lymphadenopathy. Lancet Oncol 2006;7:472–479.10.1016/S1470-2045(06)70700-8)| false
• Search Google Scholar
• Export Citation

Dong Z, Wang H, Xu M, et al.. Intermittent hormone therapy versus continuous hormone therapy for locally advanced prostate cancer: a meta-analysis. Aging Male 2015;18:233–237.

• Crossref
• PubMed
Dong Z, Wang H, Xu M, . Intermittent hormone therapy versus continuous hormone therapy for locally advanced prostate cancer: a meta-analysis. Aging Male 2015;18:233–237.10.3109/13685538.2015.106524526225795)| false
• Search Google Scholar
• Export Citation

Hussain M, Tangen CM, Berry DL, et al.. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013;268:1314–1325.

• Crossref
• PubMed
Hussain M, Tangen CM, Berry DL, . Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013;268:1314–1325.10.1056/NEJMoa1212299)| false
• Search Google Scholar
• Export Citation

Boevé LM, Hulshof MC, Vis AN, et al.. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomized clinical trial: data from the HORRAD trial. Eur Urol 2019;75:410–418.

• PubMed
Boevé LM, Hulshof MC, Vis AN, . Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomized clinical trial: data from the HORRAD trial. Eur Urol 2019;75:410–418.)| false
• Search Google Scholar
• Export Citation

Parker CC, James ND, Brawley CD, et al.. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomized controlled phase 3 trial. Lancet 2018;392:2353–2366.

• Crossref
• PubMed
Parker CC, James ND, Brawley CD, . Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomized controlled phase 3 trial. Lancet 2018;392:2353–2366.10.1016/S0140-6736(18)32486-330355464)| false
• Search Google Scholar
• Export Citation

Fizazi K, Shore N, Tarnmela T, et al.. Darolutamide in non-metastatic, castration-resistant prostate cancer [published online February 21, 2019]. N Engl J Med, doi: 10.1056/NEJMoa1815671

• PubMed
Fizazi K, Shore N, Tarnmela T, . Darolutamide in non-metastatic, castration-resistant prostate cancer [published online February 21, 2019]. N Engl J Med, doi: 10.1056/NEJMoa1815671)| false
• Search Google Scholar
• Export Citation

Marshall CH, Fu W, Wang H, et al.. Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage. Prostate Cancer Prostatic Dis 2019;22:59–65.

• Crossref
• PubMed
Marshall CH, Fu W, Wang H, . Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage. Prostate Cancer Prostatic Dis 2019;22:59–65.3017122910.1038/s41391-018-0086-1)| false
• Search Google Scholar
• Export Citation

Schweizer MT, Antonarakis ES, Bismar TA, et al.. Genomic characterization of prostatic ductal adenocarcinoma identifies a high prevalence of DNA repair gene mutations. [published online April 18, 2019]. J Clin Oncol Precis Oncol, doi: 10.1200/PO.18.00327

• PubMed
Schweizer MT, Antonarakis ES, Bismar TA, . Genomic characterization of prostatic ductal adenocarcinoma identifies a high prevalence of DNA repair gene mutations. [published online April 18, 2019]. J Clin Oncol Precis Oncol, doi: 10.1200/PO.18.00327)| false
• Search Google Scholar
• Export Citation

Abida W, Cheng ML, Armenia J, et al.. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade [published online December 27, 2018]. JAMA Oncol, doi: 10.1001/jamaoncol.2018.5801

• PubMed
Abida W, Cheng ML, Armenia J, . Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade [published online December 27, 2018]. JAMA Oncol, doi: 10.1001/jamaoncol.2018.5801)| false
• Search Google Scholar
• Export Citation

Antonarakis ES, Shaukat F, Isaacsson Velho P, et al.. Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations. Eur Oncol 2019;75:378–382.

• PubMed
Antonarakis ES, Shaukat F, Isaacsson Velho P, . Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations. Eur Oncol 2019;75:378–382.)| false
• Search Google Scholar
• Export Citation